The receptor for hyaluronic acid-mediated motility (RHAMM) is upregulated in various cancers. We previously screened genes upregulated in human hepatocellular carcinomas for their metastatic function in a mouse model of pancreatic neuroendocrine tumor (PNET) 
Metastasis accounts for 90% of cancer deaths. We developed a mouse model of well-defined multistage tumorigenesis: RIP-Tag; RIP-tva to identify metastatic factors [1] . We identified that the receptor for hyaluronic acid (HA)-mediated motility, isoform B (RHAMM B ), significantly promotes liver metastasis of pancreatic neuroendocrine tumors (PNET) in RIP-Tag; RIP-tva mouse models [2] . Expression of RHAMM is restricted in normal adult tissues, but is upregulated in cancers [3, 4] . Increased production of glycosaminoglycan, HA, is correlated with increased migration and invasion in aggressive cancers [5] . CD44 and RHAMM are two major HA receptors. The roles of CD44 isoforms in cancer have been studied extensively, but the functions of RHAMM isoforms in tumorigenesis are less clear. RHAMM encodes 18 exons and alternative splicing generates different isoforms. RHAMM A includes all 18 exons and RHAMM B lacks exon 4 ( Fig. 1a) . Here we aimed to determine the clinical relevance of RHAMM A and RHAMM B isoforms and their functions in pancreatic cancer.
RHAMM B , but not RHAMM A , is upregulated in human PNET liver metastases
To investigate RHAMM expression in human PNETs, a tissue microarray consisting of 83 PNETs was immunostained for RHAMM. RHAMM was not detectable in the normal pancreas, while 54 of 83 (65%) PNETs exhibited cytoplasmic staining using an antibody that recognizes common region in RHAMM isoforms (Fig. 1b) . Because isoform-specific RHAMM antibodies were not available, we investigated the mRNA levels of RHAMM and RHAMM B by performing RNA-Seq analysis on 27 primary PNETs and 12 liver metastases, using 89 human islets from NCBI Gene Expression Omnibus database for comparison. Consistent with our immunohistochemical data, normal islets had very low RHAMM A and RHAMM B mRNA (Fig. 1c) . RHAMM B was significantly higher than RHAMM A in both primary and metastatic PNETs, suggesting that RHAMM B is the predominant isoform naturally expressed in PNETs. Although RHAMM A levels in primary tumors were significantly higher than those in normal islets (p = 0.0002), RHAMM A levels in metastatic tumors were not significantly higher than those in normal islets (p = 0.8928). The mRNAs of RHAMM A and RHAMM B were readily detectable in additional primary PNETs and metastases by RT-qPCR using isoform-specific primers (Additional file 1: Figure S1A-B) .
We compared metastatic potential of RHAMM A to RHAMM B in RIP-Tag; RIP-tva models of spontaneous metastasis and tail vein assays [1, 2] . In contrast to RHAMM B ,
RHAMM
A did not promote spontaneous metastasis (Additional file 2: Table S1 ). Then, we generated N134 cells overexpressing RHAMM A (N134-RHAMM A ). N134 is a cell line derived from a PNET of RIP-Tag; RIP-tva mouse [1] . Although there were more RHAMM A than RHAMM B for unknown reasons (Fig. 1d) , only one visible tumor was found in 5 immunodeficient NOD/scid-IL2Rgc knockout (NSG) mice receiving N134-RHAMM A cells after 5 weeks, while all 5 mice receiving N134-RHAMM B cells developed large liver metastases within 5 weeks (Fig. 1e and Additional file 1: Figure S2A ). To detect micrometastases, we performed immunostaining for synaptophysin, a neuroendocrine marker. Mice receiving N134 cells and N134-RHAMM A cells had an average of 1.8 and 0.6 liver micrometastases, respectively (Additional file 1: Figure S2B ). These data suggested that the unique 15-amino acid-stretch, ESQKNDKDLKILEKE, which is present in RHAMM A but not in RHAMM B
, inhibits the metastatic function of RHAMM.
B is crucial for the metastatic potential of human
PNET cell line BON1-TGL
BON1 is the most utilized human PNET cell line and was established from a peri-pancreatic lymph node in a patient with metastatic PNET. We found that BON1 had much higher expression of RHAMM B than RHAMM A as determined by RNA-Seq (Fig. 2a) . We performed shRNA-mediated knockdown of total RHAMM to investigate whether this reduces metastasis of BON1-TGL cells, which carry the thymidine kinase/green fluorescent protein /luciferase fusion reporter (TGL). Knockdown of RHAMM by shRNA was confirmed (Fig. 2b, c) . We used an orthotopic model of PNET liver metastases by injecting cells into the spleen of NSG mice [6] . Mice receiving control cells developed an average of 82.5 liver metastases after 3 weeks, while mice receiving BON1-TGL-shRHAMM cells developed an average of 17 liver metastases with significantly lowered tumor burden ( Fig. 2d-f ).
To determine whether even higher RHAMM B levels would further enhance metastasis of BON1-TGL cells, we generated BON1-TGL cells overexpressing RHAMM B (Fig. 2g) . We injected the cells into NSG mice via intracardiac injection. The increased levels of RHAMM B enhanced metastasis of BON1-TGL in mice throughout the mouse body as visualized by bioluminescence imaging and signals from multiple organs were higher in mice receiving BON1-TGL-RHAMM B than those in mice receiving BON1-TGL overexpressing a control vector (Fig. 2h) . Notably, we observed macrometastases at the adrenal glands of mice receiving BON1-TGL-RHAMM B , but not in control mice (Fig. 2i) . Taken together, RHAMM B is crucial for PNET metastasis.
RHAMM
B is upregulated in human pancreatic ductal adenocarcinoma (PDAC) and correlates with poor survival PDAC is the most common pancreatic cancer type. It was shown that total RHAMM is upregulated in primary PDAC by RT-qPCR of 14 matched tumors and adjacent normal tissues [7] . To compare RHAMM A and RHAMM B levels in PDAC, we analyzed publicly available The Cancer Genome Atlas (TCGA) datasets. Both RHAMM A and RHAMM B were expressed at significantly higher levels in PDAC than in normal pancreatic tissues, and RHAMM B was substantially higher than RHAMM A (Fig. 3a) . Survival analysis showed that high RHAMM levels were correlated with a worse outcome (Fig. 3b) . Furthermore, patients with high RHAMM B had inferior survival compared to those with high RHAMM A (Fig. 3c, d Figure S3A-B) . We previously showed that EGFR signaling is activated in N134-RHAMM B cells and an EGFR inhibitor, gefitinib, induces apoptosis of N134-RHAMM B cells [2] . These findings led us to hypothesize that enhanced EGFR signaling involves RHAMM B -induced metastasis. To test this hypothesis, we used two different shRNAs targeting mouse EGFR (S7 and S9) as well as a control shRNA targeting LacZ (shLacZ). shEGFR(S7 and S9) decreased the levels of both EGFR and p-ERK1/2, a downstream target of EGFR signaling, with S7 exhibiting a better knockdown efficiency than S9 (Fig. 3e) .
In tail vein metastasis assays, mice receiving N134-RHAMM (Fig. 3f ). An additional cohort of mice injected with N134-RHAMM B -shEGFR(S7) still did not develop metastases 7 weeks post-injection, and only a mean of 0.5 liver macrometastases appeared in mice injected with N134-RHAMM B -shEGFR(S9) at this time point (Fig. 3f ) .
We investigated whether a constitutively active form of EGFR, EGFR*, is sufficient to recapitulate RHAMM B activity in metastasis. Five of the 8 RIP-Tag; RIP-tva mice receiving RCASBP-EGFR* developed pancreatic lymph node metastases (62.5%) and 2 developed liver metastases (25%) (Additional file 2: Table S1 ). We generated N134 cells overexpressing EGFR* (N134-EGFR*) for experimental metastasis (Fig. 3g) . While no metastasis was found in mice receiving control N134-Luciferase after 6 weeks, an average of 6 liver macrometastases was detected in mice receiving N134-EGFR* (Fig. 3h) . Although EGFR* promotes liver metastasis of PNETs in both spontaneous and experimental metastasis mouse models, the degree of metastasis is less than that of RHAMM B (Additional file 2: Table S1 and Fig. 3h) 
Additional files
Additional file 1: Figure S1 . RT-qPCR analysis of RHAMM A (A) and RHAMM B (B) in 9 primary human PNETs and 3 metastatic PNETs from the livers. B _shLacZ, N134_RHAMM B _shEGFR(S7), or N134_RHAMM B _shEGFR(S9) cells were injected into the tail vein of NSG mice (n = 5 for each group). At the indicated time points, the recipient mice were euthanized to survey for metastatic sites and incidence. The number of liver macrometastases was recorded. g Western blot analysis of p-Erk1/2 and total Erk from N134 overexpressing luciferase (control), and N134_EGFR*. h N134 cells overexpressing luciferase (Luc), N134_EGFR* (EGFR*), N134_RHAMM B (RHAMM B ) were injected into the tail vein of NSG mice (n = 5, each group). Five weeks later (for Luc and EGFR* groups) or when mice were lethargic (for RHAMM B ), mice were euthanized to survey for metastatic sites and incidence. *: p < 0.0001, One-way ANOVA and pairwise comparison with Tukey's adjustment
